Page last updated: 2024-12-05

anserine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Anserine: A dipeptide containing BETA-ALANINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anserine : A dipeptide comprising of beta-alanine and 3-methyl-L-histidine units. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID112072
CHEMBL ID448301
CHEBI ID18323
SCHEMBL ID34255
MeSH IDM0001286

Synonyms (42)

Synonym
(2s)-2-[(3-ammoniopropanoyl)amino]-3-(1-methyl-1h-imidazol-5-yl)propanoate
unii-hdq4n37ugv
hdq4n37ugv ,
einecs 209-545-0
CHEBI:18323 ,
n(alpha)-(beta-alanyl)-n(pros)-methylhistidine
beta-alanyl-n(pai)-methyl-l-histidine
anserine
584-85-0
beta-alanyl-n(pi)-methyl-l-histidine
C01262
CHEMBL448301
n-beta-alanyl-3-methyl-l-histidine
l-anserine
A831896
AKOS015896389
anserine [who-dd]
l-histidine, .beta.-alanyl-3-methyl-
anserine [inci]
l-histidine, n-.beta.-alanyl-3-methyl-
histidine, n-.beta.-alanyl-3-methyl-, l-
anserine [mi]
S6141
SCHEMBL34255
h-?-ala-his(3-me)-oh
(2s)-2-(3-aminopropanamido)-3-(1-methyl-1h-imidazol-5-yl)propanoic acid
I11595
MYYIAHXIVFADCU-QMMMGPOBSA-N
l-n-beta-alanyl-3-methyl-histidine
l-n-b-alanyl-3-methyl-histidine
n-b-alanyl-3-methyl-l-histidine
HY-113354
CS-0062279
DTXSID30973950
Q415335
h-beta-ala-his(3-me)-oh
AS-19301
(2~{s})-2-(3-azanylpropanoylamino)-3-(3-methylimidazol-4-yl)propanoic acid
8v3 ,
(s)-2-(3-aminopropanamido)-3-(1-methyl-1h-imidazol-5-yl)propanoic acid
na-(3-aminopropanoyl)-np-methyl-l-histidine
(s)-2-(3-aminopropanamido)-3-(1-methyl-1h-imidazol-5-yl)propanoicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, alongside this indispensable role for cell survival and growth, glucose is intrinsically toxic by reacting with primary amines such as lysine in proteins in a non-enzymatic glycation process (a."( Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines.
Szwergold, BS, 2005
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" Moreover, the crossover study suggests that there was no significant difference in absorption under curves of anserine between anserine alone and anserine-containing diet, whereas there was significant difference in the peak concentration of anserine."( Intestinal absorption and blood clearance of L-histidine-related compounds after ingestion of anserine in humans and comparison to anserine-containing diets.
Kubomura, D; Masui, A; Matahira, Y; Matsuda, H, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Balenine has a much better bioavailability and stability in human circulation upon acute ingestion, compared to carnosine and anserine."( No Effect of Acute Balenine Supplementation on Maximal and Submaximal Exercise Performance in Recreational Cyclists.
Bourgois, JG; Croubels, S; De Baere, S; de Jager, S; Derave, W; Jäger, R; Lievens, E; Purpura, M; Van Damme, S, 2023
)
0.91
" The aim of this study was to elucidate the stability of balenine in the systemic circulation and its bioavailability in humans following acute supplementation."( Acute balenine supplementation in humans as a natural carnosinase-resistant alternative to carnosine.
Bourgois, JG; Croubels, S; De Baere, S; de Jager, S; Derave, W; Jäger, R; Lievens, E; Purpura, M; Van der Stede, T; Vermeulen, A, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Carnosine showed a trend for dose-response between non-consumers, low consumers and high consumers for all meat categories, while in combination with other biomarkers the difference was significant."( The anserine to carnosine ratio: an excellent discriminator between white and red meats consumed by free-living overweight participants of the PREVIEW study.
Cuparencu, C; Dragsted, LO; Poppitt, SD; Raben, A; Rinnan, Å; Silvestre, MP, 2021
)
0.62
" Three studies were conducted to establish dosing and timing guidelines concerning carnosine and anserine intake and to unravel the mechanism underlying the ergogenic effects."( The ergogenic effect of acute carnosine and anserine supplementation: dosing, timing, and underlying mechanism.
Aldini, G; Blancquaert, L; Bourgois, JG; Croubels, S; De Baere, S; de Jager, S; Derave, W; Gilardoni, E; Lievens, E; Regazzoni, LG; Van der Stede, T, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
beta-alanine derivative
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Histidine Metabolism1735
beta-Alanine Metabolism927
GABA-Transaminase Deficiency927
Histidinemia1735
Ureidopropionase Deficiency927
Carnosinuria, Carnosinemia927

Bioassays (7)

Assay IDTitleYearJournalArticle
AID382998Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 200 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
AID382995Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 20 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
AID382996Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 50 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
AID382993Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 5 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
AID382994Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 10 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
AID382992Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 2 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
AID382997Antioxidant activity against copper-induced lipid peroxidation in human LDL assessed as inhibition of malondialdehyde formation at 100 uM relative to control2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (288)

TimeframeStudies, This Drug (%)All Drugs %
pre-199095 (32.99)18.7374
1990's37 (12.85)18.2507
2000's46 (15.97)29.6817
2010's58 (20.14)24.3611
2020's52 (18.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (3.88%)5.53%
Reviews14 (4.53%)6.00%
Case Studies3 (0.97%)4.05%
Observational1 (0.32%)0.25%
Other279 (90.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]